Moderna and Merck Report Positive Phase 3 Results for Personalized Cancer Therapy
· Texas Border Business
Moderna and Merck are making strides in cancer treatment with their personalized mRNA therapy, intismeran autogene, combined with Keytruda, following successful Phase 3 trial results for high-risk melanoma patients. This therapy aims to enhance the immune system's ability to identify and combat cancer cells tailored to individual tumor characteristics. Moderna's CEO, Stéphane Bancel, indicated that the companies are preparing to engage with regulators and share detailed findings with the medical community. The Phase 3 study showed significant improvement over Keytruda alone for patients with completely resected Stage IIB-IV melanoma, although FDA approval is still pending.
AI summary · Source: Texas Border Business →
